About us
Our Interest
Prostate cancer is one of the most commonly diagnosed types of cancer in the world. Despite a lower risk of disease progression, over 80% of favourable intermediate-risk prostate cancer patients in Australia are treated with radical treatments, like radiation therapy and surgical solutions. These radical treatments can be costly and often have additional symptoms or risks. Not all patients require such immediate radical treatments. The current standard clinical assessments lack the accuracy needed to reliably predict which patients' cancers will progress and which will remain indolent.
Our Mission
We believe better-informed patients make better-informed treatment decisions. We want to investigate whether genomic testing can be used to: identify men at lower risk of prostate cancer progression, track their prostate cancer, and manage it through active surveillance rather than immediate radical therapy. To do this, we are conducting a 10-year clinical trial. More details on the trial itself and how you can participate may be found below.
Why Should I Get Involved?
Real-Life Impact: Your Participation Makes a Difference
Alongside patient experience and feedback, clinical research is integral to improving patient health outcomes. Investigating improvements, like genetic testing, helps us understand what will make the patient experience easier. Moreover, genetic testing has already helped thousands of people make informed health decisions.
For example, genetic information has enabled breast cancer risk identification (BRCA1 & BRCA2). This has supported informed decision-making in breast cancer patients, allowing for early detection and timely interventions. Likewise, your participation could contribute to advancements in the current standard of care for prostate cancer, to benefit you and future generations.
Find Out More
Our Partners
Click on their logos to learn more about who they are.
With special thanks to the ANZUP patient consulting advisory panel for providing feedback on this trial and website.
